ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company offers ABL301, which is in the phase 1 clinical stage for the treatment of parkinson's disease; ABL503 and ABL111 that is in phase 1 clinical stage for the treatment of solid tumor; and ABL102 for the treatment of solid and blood tumor. It also provides ABL103 for the treatment solid cancers; ABL104 for the treatment of solid tumor; and ABL105, which is in phase 1 clinical stage for the treatment of solid tumor. ABL Bio Inc. was incorporated in 2016 and is based in Seoul, South Korea.
Frequently asked questions
What sector does ABL Bio Inc (298380) operate in?
ABL Bio Inc belongs to the Energy sector and operates in the Biotechnology industry.
What is ABL Bio Inc (298380) current stock price?
As of the latest data, ABL Bio Inc stock price is ₩86,800, with a previous close of ₩86,800.
What is ABL Bio Inc (298380) current market capitalization?
ABL Bio Inc market cap is approximately 4.86 trillion.
Does ABL Bio Inc (298380) pay dividends?
No. ABL Bio Inc does not pay a dividend.
What is ABL Bio Inc (298380) beta (volatility) score?
ABL Bio Inc has a beta of 0.226, indicating lower volatility than the overall market.
